SCHEMBL880284

SCHEMBL880284

O=C1CC(c2ccc(Cl)cc2)c2cc3c(cc2N1)OCO3

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.85
LMNA P02545 4/20 0.76
ALDH1A1 P00352 2/20 0.71
L3MBTL1 Q9Y468 1/20 0.71
THRB P10828 1/20 0.65
SMN1; SMN2 Q16637 7/20 0.65
MAPT P10636 3/20 0.65
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
HTT P42858 1/20 0.56
TSHR P16473 2/20 0.54
MEN1 O00255 1/20 0.54
MAPK1 P28482 1/20 0.54
KMT2A Q03164 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
ALOX15 P16050 1/20 0.52
RAB9A P51151 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10090752 0.86 LMNA (0.76) TP53LMNAALDH1A1L3MBTL1THRB
SCHEMBL880292 0.86 LMNA (0.71) TP53LMNAALDH1A1L3MBTL1THRB
SCHEMBL880278 0.84 SMN1; SMN2 (0.73) TP53LMNAALDH1A1L3MBTL1THRB
SCHEMBL10280606 0.81 SMN1; SMN2 (0.65) TP53LMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL880439 0.79 LMNA (0.71) TP53LMNAALDH1A1L3MBTL1THRB
SCHEMBL19286329 0.79 LMNA (0.71) TP53LMNAALDH1A1L3MBTL1THRB
SCHEMBL880309 0.79 LMNA (0.71) TP53LMNAALDH1A1L3MBTL1THRB
SCHEMBL15289662 0.79 ALDH1A1 (0.65) TP53LMNAALDH1A1L3MBTL1THRB
SCHEMBL10090742 0.78 TP53 (0.76) TP53LMNAALDH1A1L3MBTL1THRB
SCHEMBL10280292 0.77 LMNA (0.75) TP53LMNAALDH1A1THRBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 US disclosed
EP-2433634-A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity The Whitehead Institute for Biomedical Research (US) 2012-03-28 EP disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity SNCA, PARK7, HTT TP53 1529/4885LMNA 525/4885ALDH1A1 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.